Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes

What is the association between oral semaglutide and recognized cardiovascular risk factors vs placebo in the SOUL randomized clinical trial?In this post hoc secondary analysis of the SOUL randomized clinical trial, oral semaglutide was associated with sustained improvements in multiple cardiovascular risk factors in high-risk participants with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease receiving standard of care.These risk factor benefits may contribute to the overall benefit of oral semaglutide on outcomes for major adverse cardiovascular events, providing supporting evidence for the use of oral semaglutide in cardiovascular risk reduction.

Corresponding Author: Sharon L. Mulvagh, MD, Division of Cardiology, Department of Medicine, Dalhousie University, QEII HSC, Halifax Infirmary site, 1796 Summer St, Ste 2148.5, Halifax, NS B3H 3A7, Canada (sharon.mulvagh@nshealth.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.